Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation - Report - MDSpire

Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation

  • By

  • Fabian Maximilian Meinert

  • Jenny Dimakos

  • Ying Cui

  • Kristian B. Filion

  • Christel Renoux

  • Antonios Douros

  • May 26, 2026

  • 0 min

Share

Clinical Report: The Impact of Direct Oral Anticoagulants and COX-2 Inhibiting NSAIDs on Gastrointestinal Bleeding Risks in Atrial Fibrillation Patients

Overview

This study investigates the gastrointestinal bleeding risks associated with the concomitant use of direct oral anticoagulants (DOACs) and COX-2 selective NSAIDs compared to nonselective NSAIDs in patients with nonvalvular atrial fibrillation (NVAF).

Background

Atrial fibrillation (AF) affects approximately 60 million individuals globally, necessitating effective anticoagulation strategies to prevent stroke. Direct oral anticoagulants (DOACs) are increasingly preferred over vitamin K antagonists for stroke prevention in AF patients. However, the concomitant use of NSAIDs, which are known to increase gastrointestinal bleeding risk, raises concerns in patients with NVAF.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • COX-2 selective NSAIDs have been shown to reduce the risk of gastrointestinal bleeding by up to 60% compared to nonselective NSAIDs.
  • NSAIDs can increase the risk of gastrointestinal bleeding by up to four times compared to nonuse.
  • There is limited data on the safety of combining DOACs with NSAIDs in patients with NVAF.
  • The study utilized data from the UK Clinical Practice Research Datalink and the Régie de l’assurance maladie du Québec.

Clinical Implications

Healthcare professionals should be aware of the gastrointestinal bleeding risks associated with NSAID use in patients on DOACs.

Conclusion

The study highlights the risks associated with gastrointestinal bleeding in patients with NVAF on DOAC therapy.

Related Resources & Content

  1. JAMA Network Open, 2024 -- COX-2–Selective NSAIDs With DOACs in Atrial Fibrillation—Analgesic Safety via Antithrombotic Stewardship
  2. Journal of General Internal Medicine, 2026 -- Severity of Gastrointestinal Bleeding in Anticoagulant Therapy with Vitamin K Antagonist or Direct Oral Anticoagulant Therapy
  3. Clinical Research in Cardiology, 2020 -- Antithrombotic Approaches for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
  4. 2024 ESC Guidelines for Management of Atrial Fibrillation: Key Points - American College of Cardiology
  5. the new gastroenterologist — Delaying DOAC after colonoscopy: Weighing the risks
  6. Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants
  7. Bleeding risk using non-steroidal anti-inflammatory drugs in anticoagulated patients with atrial fibrillation: a nationwide cohort study
  8. 2024 ESC Guidelines for Management of Atrial Fibrillation: Key Points - American College of Cardiology
  9. Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation | Atrial Fibrillation | JAMA Network Open | JAMA Network
  10. Nonsteroidal Anti-Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis - PubMed

Original Source(s)

Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation

  • by Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros

  • May 26, 2026

Related Content

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Medical Oddities: Can a Home Be Preventive Care?

This week’s medical plot twists involved ants, architecture, and auditory hallucinations.

Patients with type 1 diabetes mellitus and recommended low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B targets – a SwissDiab study